Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07768345 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Learn About Revaccination With a Vaccine Called RSVpreF in Immunocompromised Adults

StatusRecruiting
PhasePhase 3
SponsorPfizer
Started2026-08-31
View on ClinicalTrials.gov ↗

Amendment history

2026-09-02
Study Status, Contacts/Locations v1
Trial sites expanded: 5 → 10 locations
Recruitment opened
Trial sites expanded: 1 → 5 locations
2026-08-12
Original filing
Pfizer
431 trials monitored
See 32 trials at risk
The purpose of this phase 3 study is to learn the safety, tolerability and immunogenicity of revaccination with RSVpreF at approximately 1-, 2-, and 3-year intervals to inform the revaccination interval in immunocompromised adults. This study is seeking participants who are 18 years of age and older and will be grouped based on prior RSV vaccination history. Participants are required to be immunocompromised per study protocol. All participants in this study will receive 1 shot to their arm of a RSVPreF vaccine. Participants will take part in this study for about 12 months and will need to visit the clinical study site at least 4 times.
Trial Details
NCT Number NCT07768345
Lead Sponsor Pfizer
Conditions Respiratory Syncytial Virus (RSV)
Enrollment 440 participants
Start Date 2026-08-31
Primary Completion 2028-02-02 (estimated)
Study Completion 2028-02-02 (estimated)
Updated on ClinicalTrials.gov 2026-09-25